BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

845 related articles for article (PubMed ID: 34648954)

  • 1. Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death.
    Tang B; Xu W; Wang Y; Zhu J; Wang H; Tu J; Weng Q; Kong C; Yang Y; Qiu R; Zhao Z; Xu M; Ji J
    Clin Immunol; 2021 Nov; 232():108872. PubMed ID: 34648954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of a ferroptosis-related gene to predict survival outcomes and the immune microenvironment in lung adenocarcinoma.
    Deng B; Xiang J; Liang Z; Luo L
    Cancer Cell Int; 2022 Sep; 22(1):292. PubMed ID: 36153508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
    Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
    Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma.
    Jin CY; Du L; Nuerlan AH; Wang XL; Yang YW; Guo R
    Aging (Albany NY); 2020 Dec; 13(3):3518-3535. PubMed ID: 33411689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel ferroptosis-related genes model for prognosis prediction of lung adenocarcinoma.
    Li F; Ge D; Sun SL
    BMC Pulm Med; 2021 Jul; 21(1):229. PubMed ID: 34256754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma.
    Yuan L; Wu X; Zhang L; Yang M; Wang X; Huang W; Pan H; Wu Y; Huang J; Liang W; Li J; Zhu X; Wang S; Guan J; Liu L
    Cancer Immunol Immunother; 2022 Feb; 71(2):399-415. PubMed ID: 34181042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 9. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
    Guo L; Li X; Liu R; Chen Y; Ren C; Du S
    Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel ferroptosis-related gene signature for prognostic prediction of patients with lung adenocarcinoma.
    Jin J; Liu C; Yu S; Cai L; Sitrakiniaina A; Gu R; Li W; Wu F; Xue X
    Aging (Albany NY); 2021 Jun; 13(12):16144-16164. PubMed ID: 34115610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma.
    Zheng M; Liu J; Bian T; Liu L; Sun H; Zhou H; Zhao C; Yang Z; Shi J; Liu Y
    Int Immunopharmacol; 2021 Jan; 90():107134. PubMed ID: 33168407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma.
    Yan Y; Gao Z; Han H; Zhao Y; Zhang Y; Ma X; Chen H
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):565-575. PubMed ID: 34746975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of prognosis and immunotherapy efficacy based on metabolic landscape in lung adenocarcinoma by bulk, single-cell RNA sequencing and Mendelian randomization analyses.
    Liu Y; Zhang X; Pang Z; Wang Y; Zheng H; Wang G; Wang K; Du J
    Aging (Albany NY); 2024 May; 16(10):8772-8809. PubMed ID: 38771130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Machine learning revealed ferroptosis features and ferroptosis-related gene-based immune microenvironment in lung adenocarcinoma.
    Luo L; Chen X; Huang F
    Chem Biol Interact; 2023 Jun; 378():110471. PubMed ID: 37061114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ferroptosis-Related Genes Are Potential Therapeutic Targets and the Model of These Genes Influences Overall Survival of NSCLC Patients.
    Zhang N; Wu Y; Wu Y; Wang L; Chen J; Wang X; Chard Dunmall LS; Cheng Z; Wang Y
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
    Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
    Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLC7A11 inhibits ferroptosis and downregulates PD-L1 levels in lung adenocarcinoma.
    Huang Z; Chen X; Wang Y; Yuan J; Li J; Hang W; Meng H
    Front Immunol; 2024; 15():1372215. PubMed ID: 38655266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.